SCAL Stock Overview
Stem Cell Authority, Ltd., a technology development company, focuses on the collection and cryogenic preservation of stem cells.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Stem Cell Authority, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0031 |
| 52 Week High | US$0.008 |
| 52 Week Low | US$0.0003 |
| Beta | 0 |
| 1 Month Change | 55.00% |
| 3 Month Change | 287.50% |
| 1 Year Change | n/a |
| 3 Year Change | -91.73% |
| 5 Year Change | 3,000.00% |
| Change since IPO | -93.80% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| SCAL | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0% | 2.4% | -3.7% |
| 1Y | n/a | 0.8% | 20.5% |
Return vs Industry: Insufficient data to determine how SCAL performed against the US Healthcare industry.
Return vs Market: Insufficient data to determine how SCAL performed against the US Market.
Price Volatility
| SCAL volatility | |
|---|---|
| SCAL Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 7.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SCAL's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine SCAL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Carlzo Cardwell | www.stemcellauthority.com |
Stem Cell Authority, Ltd., a technology development company, focuses on the collection and cryogenic preservation of stem cells. It specializes in the collection and cryogenic preservation of the hematopoietic stem cells from the umbilical cord blood; and the Miracle Mesenchymal stem cells from the Wharton’s jelly inside the umbilical cord of a newborn child. The company’s technology enables birthing professionals with a stem cell preservation program to serve their maternity patients in the United States.
Stem Cell Authority, Ltd. Fundamentals Summary
| SCAL fundamental statistics | |
|---|---|
| Market cap | US$1.09m |
| Earnings (TTM) | US$1.83m |
| Revenue (TTM) | US$3.33m |
0.0x
P/E Ratio0.0x
P/S RatioIs SCAL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SCAL income statement (TTM) | |
|---|---|
| Revenue | US$3.33m |
| Cost of Revenue | US$1.06m |
| Gross Profit | US$2.27m |
| Other Expenses | US$436.45k |
| Earnings | US$1.83m |
Last Reported Earnings
Aug 31, 2009
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did SCAL perform over the long term?
See historical performance and comparison